1Q25 EARNINGS CONFERENCE CALL





PagueMenos () extrafarma

Disclaimer

This document may contain certain forward-looking statements and information related to the Company reflecting current views and/or expectations of the Company and its Management concerning its performance, businesses and future events. Forward-looking statements include, without limitation, any statement that has a forecast, indication or estimates and projections of future results, performance or objectives, as well as words such as "we believe", "we anticipate", "we expect", "we estimate", "we project", among other words with similar meaning. Although the Company and its management believe that such forward-looking estimates and statements are based on reasonable assumptions, they are subject to risks, uncertainties and future events and are issued in the light of information that is currently available. Any forward-looking statements refer only to the date on which they were issued, and the Company is not responsible for updating or revising them publicly after the distribution of this document due to new information, future events or other factors. Investors should be aware that a number of important factors cause actual results to differ materially from such plans, objectives, expectations, projections and intentions as expressed in this document.

In view of the aforementioned risks and uncertainties, the prospective circumstances and events discussed in this document may not occur, and the Company's future results may differ significantly from those expressed or suggested in these forward-looking statements. Forward-looking statements involve risks and uncertainties and are not guarantees of future events. Therefore, investors should not make any investment decision based on the forward-looking statements that may be contained herein.

Market and certain competitive position information, including market projections mentioned herein were obtained from in-house surveys, market research, public information and business publications. Although we have no reason to believe that any of this information or these reports are inaccurate in any material respect, we do not independently verify market position, growth rate, competitive position or any other data provided by third parties or other industry publications. The Company is not responsible for the accuracy of such information.

Certain percentages and other amounts included in this document have been rounded up to facilitate their presentation. The scales of the graphs of the results can appear in different proportions, to optimize the demonstration. Accordingly, the numbers and graphs presented may not represent the arithmetic sum and the appropriate scale of the numbers that precede them, and may differ from those presented in the financial statements.

Since 2019 our financial Statements have been prepared in accordance with IFRS 16, which changed the criteria for the recognition of rental contracts. To better represent the economic reality of the business, the numbers in this presentation are presented under the previous standard, IAS 17 / CPC 06. Reconciliation to IFRS 16 can be found in a dedicated section of our Earnings Release.



People, Culture and Purpose


A significant part of the result is supported by our intangible assets



PagueMenos **()** extrafarma

Consistent Performance

Five consecutive quarters of improving key financial metrics



1Q25 Highlights

🚹 PagueMenos 🚯 extrafarma

Strong sales performance driving 55% EBITDA growth



GROSS REVENUE R\$3.6 billion (+17.1% vs 1Q24)

with same store sales of 17.0%



MARKET SHARE

6,5% market share

+41bps vs 1Q24 with gains in all regions



ADJUSTED EBITDA

R\$150.3 million (+55.2% vs 1Q24)

EBITDA margin of 4.1% (+1.0p.p. vs 1Q24)



DIGITAL CHANNELS

R\$639 million (+53.6% vs 1Q24)

17.6% of total sales (+4.2p.p. vs 1Q24)



NET INCOME LTM

R\$ 188.2 million in the last 12 months +5x vs 1Q24 LTM



CASH FLOW¹ LTM

R\$487 million (+16% vs 1Q24 LTM)






Sales Performance




Same store sales ~4x above inflation, well balanced across regions and banners










Sustainable Growth



Strong performance supported by structural drivers related to operational improvements





¹ With purchases in the last 12 months



Digital Channels

Consistent acceleration continues contributing to sales performance









- **+66%** e-commerce growth
- +78% app growth
- **+300%** WhatsApp growth
- **Highest** Click&Collect share (57% of sales)
- **Highest** daily sale (surpassing Black Friday '24)

Market Share

Market share gains across all regions



MARKET SHARE EVOLUTION BRAZIL¹ (% of total market)




Source: IQVIA

¹ For the last 4 quarters, the IQVIA database published in March/25 was used. For previous quarters, the databases reported in their respective periods were considered.

Growth Components

PagueMenos **Q** extrafarma

Mature stores growth of +2.5x above the market average



Source: IQVIA


Note: IQVIA methodology normalizes sales prices among players, which may cause the growth in R\$ CPP to differ from the actual performance. New stores include stores opened in the last 24 months.

Performance vs Peers

Outperformance across all regions

AVERAGE SALES YOY GROWTH PER STORE¹

(% variation R\$ CPP - 1Q25 vs 1Q24)



Associations Independents Chains PagueMenos/Extrafarma

PagueMenos () extrafarma

Gross Profit and Margin

Targeted commercial strategy driving sales and cash flow





- Reduction in loss rate
- Adjustment to present value (APV)




- Relevant growth in RX
- Higher Digital share
- Accelerated inventory turnover
- Price competitiveness

PagueMenos () extrafarma

Selling Expenses


Strong operational leverage driving a 1.2 p.p. expense dilution



□ PagueMenos ② extrafarma

G&A Expenses


0.4 p.p. YoY dillution, returning to the pre-Extrafarma normalized level




□ PagueMenos ② extrafarma

Adjusted EBITDA

EBITDA growth of 55.2% with a 1.0 p.p. margin gain







Net Income



Profitability recovery through growth and leverage, despite higher interest rates











Cash Cycle

A structural reduction of 9 days in inventory led to a 10-day improvement in the cash cycle vs. 1Q24






¹ The cash conversion cycle calculation excludes the effects of adjustments to present value (APV), commercial agreements, and recoverable taxes.

Indebtedness and Cash Flow


Record operating cash flow, enabling deleveraging and supporting investments



¹ Net debt definition for covenant purposes, as per the debenture indentures. Considers the balance of loans and bank financing net of the cash position.

² Adjusted for receivables anticipation.

Increasing return on invested capital, driven by operational improvements



¹ The calculation methodology considers the Operating Income (excluding general and administrative expenses) accumulated over the last 12 months after taxes (Income Tax = 34%), divided by the average invested capital over the last four quarters (working capital + fixed assets).



Our Journey So Far

ONBOARDING

STRUCTURING OF OPERATIONAL PILLARS

IT'S NOW...

1Q24

2Q24

3Q24

4Q24

1Q25

- Active listening
- Diagnosis
- Setting priorities
- Structuring operational missions
- C-Level training

- Quick-wins acceleration
- Culture reinforcement
- Review of strategic planning
- Conclusion of Extrafarma integration
- Unfolding of the strategic plan
- Engagement of the entire organization



SAVE THE DATE

São Paulo, SP May 22, 9:00 AM



Continuous Care PositioningRenato Camargo
CMO



Customer JourneyRobledo Castro
CTO



People that "Does Well" Rosi Puccetti CHRO



Commercial Levers
Walace Siffert
CCO



Expansion as a Strategic PillarCarlos Fernandes
COO



Value Generation and Capital AllocationLuiz Novais
CFO



Strategic Plan OverviewJonas Marques
CEO



